Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs KLA Corp. — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while KLA Corp. trades at $195.57 (market cap $256.72B). The key difference: KLA Corp. is far larger — about 42.5× Iovance Biotherapeutics Inc. Common Stock's market cap, and KLA Corp. pays a 0.47% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and KLA Corp. for 60 Days on average.
| IOVA | KLAC | |
|---|---|---|
Market Cap | $6.04B | $256.72B |
Volume | 14,805,993 | 9,970,753 |
Sector | Health | Technology |
52-Week High | $14.82 | $301.71 |
52-Week Low | $1.81 | $98.28 |
Typical Hold Time | 0 Days | 60 Days |
Enterprise Value | $5.97B | $257.97B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
KLA Corporation (KLAC) trades at $195.57, down 0.64% on the day, with strong technical momentum showing bullish moving averages and key support at $193. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $1.05 versus $1.00 estimate, revenue growth accelerating to $12.16B in 2025, and exceptional profitability metrics including 35.57% net income margin and 87.5% ROE. Recent news highlights AI-driven demand boosting KLA's $12.57B backlog and competitive positioning against AMAT and ASML.
KLA presents a compelling growth opportunity with analyst consensus price target of $223.88 (14.5% upside) and strong institutional support, though elevated valuation ratios (P/E 53.75, P/S 19.12) and semiconductor cycle sensitivity warrant caution. The stock's outlook remains positive driven by AI infrastructure spending and advanced packaging growth, with key risks including competition intensity and potential margin pressure from increased investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
